Dyslipidemia patients display higher levels of pro-inflammatory
monocytes than healthy subjects.
We also determined the levels of M1- and M2-like monocytes in healthy
subjects and those with dyslipidemia based on the CD14 expression (Fig
3A). There is a higher percentage of M1-like monocytes expressing CD14
high (++) (p= 0.0003, 45.99% ± 23.23% vs 57.52% ±
26.47%, arithmetic mean and SD; Fig 3B), and a higher percentage of
M2-like monocytes expressing CD14 dim (+) in the
subjects with dyslipidemia compared to the control group (p
<0.0001, 3.8% ± 6.67% vs 3.66% ± 2.22%, arithmetic mean
and SD; Fig 3C). When evaluating the
CD14++CD68+CD80+and
CD14+CD163+CD206+populations, we found higher
percentages of pro-inflammatory monocytes in the dyslipidemia patients
(p= 0.0355, 51.65%, 60.80%-26.53% vs 28%, 39.13%-13.63%, median
and IQR; Fig 3B). However, no differences between M2-like monocytes from
healthy and dyslipidemia groups, were found (p= 0.5383; Fig 3C).